Interpace Biosciences (OTCMKTS:IDXG) Share Price Passes Above 200-Day Moving Average – What’s Next?

Interpace Biosciences, Inc. (OTCMKTS:IDXG) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.68 and traded as high as $1.7030. Interpace Biosciences shares last traded at $1.7022, with a volume of 6,886 shares changing hands.

Interpace Biosciences Stock Performance

The company has a 50 day moving average of $1.85 and a two-hundred day moving average of $1.68. The stock has a market capitalization of $7.54 million, a PE ratio of -34.04 and a beta of 0.59.

Interpace Biosciences (OTCMKTS:IDXG) last released its quarterly earnings results on Tuesday, May 12th. The business services provider reported $0.03 EPS for the quarter. The company had revenue of $9.03 million during the quarter. Interpace Biosciences had a return on equity of 219.07% and a net margin of 65.25%.

About Interpace Biosciences

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.